"Immunodominant Epitopes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Subunits of the antigenic determinant that are most easily recognized by the immune system and thus most influence the specificity of the induced antibody.
| Descriptor ID |
D016056
|
| MeSH Number(s) |
D23.050.550.500
|
| Concept/Terms |
Immunodominant Epitopes- Immunodominant Epitopes
- Immunodominant Determinants
- Determinants, Immunodominant
- Immunodominant Domains
- Domains, Immunodominant
- Immunodominant Sites
- Sites, Immunodominant
- Immunodominant Regions
- Regions, Immunodominant
- Antigenic Determinants, Immunodominant
- Determinants, Immunodominant Antigenic
- Immunodominant Antigenic Determinants
- Epitopes, Immunodominant
|
Below are MeSH descriptors whose meaning is more general than "Immunodominant Epitopes".
Below are MeSH descriptors whose meaning is more specific than "Immunodominant Epitopes".
This graph shows the total number of publications written about "Immunodominant Epitopes" by people in this website by year, and whether "Immunodominant Epitopes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1999 | 1 | 1 | 2 |
| 2001 | 1 | 0 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 2 | 1 | 3 |
| 2005 | 4 | 0 | 4 |
| 2006 | 0 | 1 | 1 |
| 2007 | 2 | 2 | 4 |
| 2008 | 0 | 2 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 9 | 6 | 15 |
| 2018 | 7 | 9 | 16 |
| 2019 | 3 | 2 | 5 |
| 2020 | 2 | 8 | 10 |
| 2021 | 5 | 8 | 13 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunodominant Epitopes" by people in Profiles.
-
Mining of linear B cell epitopes of SARS-CoV-2 ORF8 protein from COVID-19 patients. Emerg Microbes Infect. 2021 Dec; 10(1):1016-1023.
-
A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters. Emerg Microbes Infect. 2021 Dec; 10(1):874-884.
-
Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. Science. 2021 10 08; 374(6564):eabh1823.
-
Structural basis of biased T cell receptor recognition of an immunodominant HLA-A2 epitope of the SARS-CoV-2 spike protein. J Biol Chem. 2021 09; 297(3):101065.
-
Antibody Response to SARS-CoV-2 Membrane Protein in Patients of the Acute and Convalescent Phase of COVID-19. Front Immunol. 2021; 12:679841.
-
SARS-CoV-2 specific memory T cell epitopes identified in COVID-19-recovered subjects. Virus Res. 2021 10 15; 304:198508.
-
SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants. Front Immunol. 2021; 12:701501.
-
Human CD4+ T cells specific for dominant epitopes of SARS-CoV-2 Spike and Nucleocapsid proteins with therapeutic potential. Clin Exp Immunol. 2021 09; 205(3):363-378.
-
Immunodominant T-cell epitopes from the SARS-CoV-2 spike antigen reveal robust pre-existing T-cell immunity in unexposed individuals. Sci Rep. 2021 06 23; 11(1):13164.
-
The landscape of antibody binding in SARS-CoV-2 infection. PLoS Biol. 2021 06; 19(6):e3001265.